Login / Signup

From Evidence to Effectiveness: Implications of the Randomized Trial to Prevent Vascular Events in HIV Study for People With Human Immunodeficiency Virus in Low- and Middle-Income Settings.

Jennifer Manne-GoehlerMohammed K AliDavid FloodVincent C MarconiWillem D F VenterMark J Siedner
Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study found a 35% reduction in major adverse cardiovascular events for people with human immunodeficiency virus who received daily pitavastatin. However, how this evidence will change practice is far from certain. Here, we outline evidence gaps and political and healthcare delivery challenges that will need to be addressed for REPRIEVE to offer public health benefits in low- and middle-income countries.
Keyphrases